



Docket No. 5195

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Haga et al.

Serial No.: 10/762,899

Filed: January 21, 2004

**For: NON-CONTACT DEVICE AND
METHOD FOR COLLAPSING
HYBRIDIZATION SUBSTRATE**

) Group Art Unit: TBA

) Examiner: TBA

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

March 3, 2004
(Date of Deposit)

Cheri Gomez
Name of Depositing Party
Cheri Gomez
Signature of Depositing Party

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449) of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) [] accompanies a new patent application submitted herewith.
 - (b) [x] is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.
 - (c) [] as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits.
 - (d) [] as far as is known to the undersigned, is filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /M V/

- (e) [] is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final action under §1.113, a notice of allowance under §1.311, whichever occurs first, and is accompanied by either the fee (\$180) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.
- (f) [] is filed after the mailing date of either a final rejection or a notice of allowance, but on or before the payment of the issue fee, and is accompanied by the fee (\$180) set forth in 37 CFR §1.17(i)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the information disclosure statement.** The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.

[If either of boxes (e) or (f) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.] The undersigned certifies that:

- [] Each item of information contained in the information disclosure statement was first cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this information disclosure statement.

Copies of items on PTO/SB/08A are supplied herewith:

[X] each [] none [] only those listed below:

Those patent(s) or publication(s) listed in the attached PTO/SB/08A form are not supplied because they were previously cited by or submitted to the Office in prior application Serial No. _____, filed _____ and relied upon in this application for an earlier filing date under 35 USC §120.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: 3/2/04



Phil N. Makrigiannis, Reg. No. 47,766
Attorney for Applicants

Correspondence Address
Customer Number 22896
Applied Biosystems Division
Appera Corporation
850 Lincoln Centre Drive
Foster City, CA 94404
(650) 638-6492 (Phone)
(650) 638-6677 (Fax)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.V./

Please type a plus sign (+) inside this box.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Do not file this form in a collection of information unless it displays a valid OMB control number.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

10

1

Complete if Known

Application Number	10/762,899
Filing Date	January 21, 2004
First Named Inventor	Haga, Douwe
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket No.	5195

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kind of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hoer Statement: This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. An assessment on the amount of time you believe it would take to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Page 108

*Please type a plus sign (+) inside this box. →

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/762,899
				Filing Date	January 21, 2004
				First Named Inventor	Haga, Douwe
				Group Art Unit	TBA
				Examiner Name	TBA
(Use as many sheets as necessary)					
Sheet	2	of	2	Attorney Docket No.	5195

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature /Mathieu Vargot/ **Date Considered** 05/10/2008

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2 hours to complete. The U.S. Office of Management and Budget has determined that this collection of information will burden individuals and businesses, particularly small entities, unless some or all of this burden is removed. If you believe this burden is excessive, please contact the Chief Information Officer, Patient and Leadership Crisis, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Washington, DC 20231. 5195 ICS

6-106-IDS